Locations:

Tag: pembrolizumab

September 16, 2024/Cancer/Research

New Studies Reinforce Benefits of Combination Treatment for Urothelial Carcinoma

Enfortumab vedotin plus pembrolizumab benefited patients, regardless of biomarker expression

December 27, 2023/Cancer/Research

A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

January 27, 2023/Cancer/Research

Pembrolizumab Following Autologous Stem Cell Transplantation Shows Promise in T-Cell Non-Hodgkin’s Lymphoma

62% of patients were progression-free at 18 months post-transplantation

June 25, 2020/Cancer/Research

Phase II Trial Evaluates Safety of Pembrolizumab plus SurVaxM in Recurrent Glioblastoma

Will cancer vaccine boost immunotherapy’s efficacy?

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

March 3, 2020/Cancer/News & Insight

Case Report: Merkel Cell Carcinoma Patients Respond to Investigational Combination Therapy

Immune checkpoint inhibitor and oncolytic viral immunotherapy produce synergistic effect

June 3, 2019/Cancer/Research

Could Immunotherapy Help Cure Cutaneous Squamous Cell Carcinoma?

Enroll patients now in KEYNOTE-630 trial

June 3, 2019/Cancer/Research

New Renal Cancer Therapy Effective in Higher Risk Groups

Another option for immunotherapy

BackPage 1 of 1Next